Vizsgálati helyszín
Spitalul Clinic Dr. I. Cantacuzino
Bucharest, 020475, RomániaEU-13 felzárkózó országMég nincs intézményhez kötve
- 16futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis12 vizsgálat
- Állapot
- Lezárult9 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Toboroz7 vizsgálat
- Még nem toboroz2 vizsgálat
- Fő szponzor
- Boehringer Ingelheim3 vizsgálat
- Ipsen3 vizsgálat
- Takeda3 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- Horizon Therapeutics Ireland Designated Activity Company2 vizsgálat
- és még 11
Futó vizsgálatok
Még nem toboroz
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549· 3. fázis· Ipsen· Forrás
Toboroz
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181· 2. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239· 2. fázis· Zura Bio Inc· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· 2. fázis· Immunovant Sciences GmbH· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155· 2. fázis· argenx· Forrás
Fut, nem toboroz
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus
2024-510584-37-00· 2. fázis· Zenas Biopharma (USA) LLC· Forrás
Fut, nem toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950· 2. fázis· Takeda· Forrás
Toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· 2. fázis· Takeda· Forrás
Fut, nem toboroz
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803· 3. fázis· AstraZeneca· Forrás
Toboroz
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842· 3. fázis· Ipsen· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Toboroz
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT06991114· 2. fázis· Artiva Biotherapeutics, Inc.· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403· 3. fázis· Ipsen· Forrás
Lezárult
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
NCT04781543· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Lezárult
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580· 2. fázis· Boehringer Ingelheim· Forrás
Lezárult
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
NCT05630820· 3. fázis· GlaxoSmithKline· Forrás
Lezárult
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
NCT05377489· 3. fázis· Grünenthal GmbH· Forrás
Toboroz
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
NCT05369052· 3. fázis· MicuRx· Forrás
Lezárult
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics
of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
2023-509782-20-00· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Hibát jelzek